BCIL licenses 'NAUROZ- A Novel Polyherbal Probiotic Formulation for Vaginosis' developed by Prof.G.P. Talwar to M/s Bipha Drug Laboratories (Pvt.) Ltd, Kottayam, Kerala

NAUROZ- A Composition for improved vaginal health, developed by Talwar Research Foundation(TRF), New Delhi was transferred through Biotech Consortium India Limited (BCIL) to M/s Bipha Drug Laboratories (Pvt.) Ltd, Kottayam, Kerala on 7th April, 2018 non-exclusively.

The technology provides a combination of the polyherbal microbicide BASANT also developed by TRF along with three meritorious strains of lactobacillus (termed Pro-vag-Health). The technology for Basant which has anti-HPV properties was licensed in June 2018 to Bipha and is nearing market readiness. As per clinical trial results, the combination of Basant with Pro-vag-Health has been found to have significant enhancement in effcicay (95%). Where Pro-vag-Health alone was unable to regress Vaginosis, impressively the combination of the two- NAUROZ was effective in nearly every woman, 19 out of 20 women. The company aims to develop a combination product which will provide relief to patients inflicted with vaginosis which is prevalent in more than 30% of the female population in India and having almost same statistics in USA.

The technology has been developed by a team led by Prof. G.P. Talwar, Former Director, National Institute of Immunology (NII), currently heading the Talwar Research Foundation. Dr. Talwar is noted Padma Bhushan and Life time achievement awardee.

The licensing of the technology has been facilitated by BCIL with its vast experience and expertise in the area of biotechnology. BCIL diligently monitors the transferred technologies to ensure that they reach from lab to market. The formulation is expected to be available in the market within a period of 12 months from Licensing.



Signing of the Agreement by Dr G. P. Talwar in the presence of Dr. N. K. Ganguly, Former DG ICMR, A. Panda, Director, NII and other dignitaries

BCIL licenses Nauroz a technology for Improved vaginal health. A tripartite License agreement was executed between Biotech Consortium India Limited, Talwar Research foundation and M/s Bipha Drug Laboratories (Pvt.) Ltd, Kottayam